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Objectives: Disuse by bed rest, limb immobilization or space ﬂight causes rapid bone loss. We
conducted the present study to investigate the therapeutic effects of zoledronic acid (ZOL),
alone and in combination with alfacalcidol (ALF) in a rat model of disuse osteoporosis.
Methods: In the present study, 3-month-old male Wistar rats had their right hind-limb immo-
bilized (RHLI) for 10 weeks to induce osteopenia, then were divided into four groups: 1 – RHLI
positive control; 2 – RHLI plus ZOL (50 g/kg, i.v. single dose); 3 – RHLI plus ALF (0.5 g/kg,
oral gauge daily); 4 – RHLI plus ALF (0.5 g/kg, oral gauge daily) plus ZOL (50 g/kg, i.v. single
dose) for another 10 weeks. One group of non-immobilized rats was used as negative con-
trol.  At the end of the treatment, the femurs were removed and tested for bone porosity,
bone  mechanical properties, and bone dry and ash weight.
Results: Combination therapy with ZOL plus ALF was more effective in decreasing bone
porosity than each drug administered as monotherapy in RHLI rats. With respect to improve-
ment in the mechanical strength of the femoral mid-shaft, the combination treatment of
ZOL  plus ALF was more effective than each drug administered as a monotherapy. Moreover,
combination therapy using ZOL plus ALF was more effective in improving dry bone and ash
weight, than single-drug therapy using ZOL or ALF in RHLI rats.
Conclusions: These data suggest that combination therapy with ZOL plus ALF represents apotentially useful therapeutic option for the treatment of disuse osteoporosis.© 2014 Elsevier Editora Ltda. All rights reserved.
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E-mail: deepak kumarkhajuria@yahoo.co.in (D.K. Khajuria).
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Efeito  combinado  do  ácido  zoledrônico  e  do  alfacalcidol  no  tratamento  da
osteoporose  por  desuso  em  ratos
Palavras-chave:
Osteoporose por desuso
Estudo com ratos
Ácido zoledrônico
Alfacalcidol
r  e  s  u  m  o
Objetivos: O desuso pelo repouso no leito, pela imobilizac¸ão de membros ou por missões
espaciais provoca a perda óssea rápida. Fez-se este estudo para investigar os efeitos ter-
apêuticos do ácido zoledrônico (ZOL), isoladamente e em combinac¸ão ao alfacalcidol (ALF),
em  um modelo de rato com osteoporose por desuso.
Métodos: Ratos Wistar machos de três meses foram submetidos à imobilizac¸ão da pata
traseira direita (IPTD) por 10 semanas para induzir a osteopenia; em seguida, foram divi-
didos em quatro grupos: 1 – IPTD para controle positivo; 2 – IPTD mais ZOL (50 g/kg, dose
única intravenosa); 3 – IPTD mais ALF (0,5 g/kg, via oral diariamente); 4 – IPTD mais ALF
(0,5 g/kg, via oral diariamente) mais ZOL (50 g/kg, dose única intravenosa) por outras 10
semanas. Um grupo de ratos não imobilizados foi usado como controle negativo. No ﬁm
do  tratamento, os fêmures foram removidos e testaram-se a porosidade do osso e suas
propriedades mecânicas, além do peso seco e das cinzas do osso.
Resultados: A terapia combinada com ZOL mais ALF foi mais eﬁcaz em reduzir a porosi-
dade  do osso do que a monoterapia com um dos fármacos administrado isoladamente em
ratos  submetidos à IPTD. No que diz respeito à melhoria da resistência mecânica da diá-
ﬁse femoral média, o tratamento combinado com ZOL mais ALF foi mais eﬁcaz do que a
monoterapia com um dos fármacos administrado isoladamente. Além disso, a terapia com-
binada com ZOL mais ALF foi mais eﬁcaz na melhoria do peso seco e das cinzas do osso do
que  a monoterapia com ZOL ou ALF em ratos submetidos à IPTD.
Conclusões: Esses dados sugerem que a terapia combinada com ZOL mais ALF representa
uma  opc¸ão terapêutica potencialmente útil para o tratamento da osteoporose por desuso.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.
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echanical loading is essential for the normal functioning
f bone tissue.1 Maintenance of skeletal integrity, bone mass
nd bone formation in weight-bearing limbs are dependent
n gravity.2 Skeletal unloading induced by prolonged cast
r splint ﬁxation, stress protection secondary to plate ﬁx-
tion of fractures, incapacitation due to chronic illness or
pinal cord injury, or weightlessness associated with orbital
pace ﬂight causes a decrease in bone mass in both human
nd animal models.2,3 Immobilization (disuse) osteoporosis
auses net bone loss as a result of an imbalance between
one resorption and bone formation.3 Hence, we have to
eep in mind that bone loss due to prolonged immobiliza-
ion increases the susceptibility to fractures in patients with
pinal cord injuries, elderly requiring bed rest and astronauts
uring long space missions. Therefore, it is very essential to
elect optimal treatment for effective management of disuse
steoporosis.
Bisphosphonates inhibit bone resorption as they are selec-
ively incorporated into osteoclasts and interfere with the
esorptive action of osteoclasts.4 Zoledronic acid (ZOL) is a
hird generation nitrogen containing bisphosphonate, and is
idely used for postmenopausal and glucocorticoid-induced
steoporosis in humans.5–8 The effect of a single treatment of
OL for immobilization-induced osteoporosis has been shown
9,10n animal studies. Although anti-resorptive agents such as
isphosphonates are effective in reducing bone loss, they are
ot able to induce formation of a new bone.7,10Alfacalcidol (1 alpha-hydroxy Vitamin D3 – ALF) is a syn-
thetic Vitamin D analog, a calcium regulating hormone, and is
frequently used in several countries to treat osteoporosis.9,11
ALF reduces parathyroid hormone levels, as a result of both
increased calcium absorption and an inhibition of the prolifer-
ation of the parathyroid gland, and also decreases the release
of pro-inﬂammatory cytokines, which contribute to osteoclast
activation. Moreover, ALF stimulates the formation and action
of osteoblasts, leading to increased bone formation.12–15 It has
been demonstrated previously that the administration of ALF
diminished the effect of immobilization in the development
of osteoporosis.9,16
ZOL and ALF are commercially available in India. ZOL is
known to inhibit osteoclast-mediated bone resorption,9,12,17
while ALF exerts both anabolic and anti-resorptive effects
on the skeleton.13,18,19 A combination of two different drugs
is believed to be a more  effective treatment than a single
treatment for osteoporosis; the combination of bisphospho-
nate and a bone anabolic drug has been used clinically
for postmenopausal osteoporosis.20,21 As immobilization-
induced bone loss involves both increased bone resorption
and decreased bone formation,3 it seems obvious to tar-
get the immobilization-induced bone loss with a combined
anti-resorptive and bone anabolic treatment regimen, such
as ZOL and ALF. The effects of a combined ZOL and ALF
treatment have previously been studied in ovariectomized
rats,17 whereas this treatment regimen has not previously
been investigated in rat model of disuse osteoporosis. Con-
sequently, the aim of the present study was to investigate the
efﬁcacy of a bone anabolic agent ALF, a bone anti-resorptive
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agent ZOL, and the combination of these two in the treat-
ment of immobilization-induced osteopenia in rats. Owing
to the different mechanisms of action of ZOL and ALF, our
hypothesis was that the combination of ZOL and ALF would
facilitate greater improvements in bone properties than either
intervention alone. We  assessed the parameters as follows;
(1) the mechanical properties in immobilized (right) and non-
immobilized (left) femoral mid-shaft; (2) the bone porosity
measurement of the immobilized (right) and non-immobilized
(left) femur;(3) measurement of immobilized (right) and non-
immobilized (left) dry bone and ash weight.
Materials  and  methods
Drugs,  chemicals  and  other  materials
ZOL and ALF were obtained from Naprod Life Sciences
(Maharashtra, India) and GlaxoSmithKline Pharmaceuticals
(Mumbai, India), respectively. Ketamine, xylazine and xylene
were obtained from Neon Pharma (Mumbai, India), Indian
Immunologicals (Hyderabad, India), and S.D. Fine chemicals
(Mumbai, India), respectively.
Experimental  animals
Twelve-week-old male Wistar rats weighing 170–180 g were
included in the study. Animals were maintained under con-
trolled temperature at 25 ± 2 ◦C with 12 h light/dark cycle with
food and water and provided ad libitum. The experiments
were conducted as per the CPCSEA (Committee for the Purpose
of Control and Supervision of Experiments on Animals) guide-
lines after obtaining ethical clearance from the Institutional
Animal Ethical Committee.
Pre-clinical  study  design
At three months of age, right hind-limb of the rats were immo-
bilized against the abdomen under ketamine (80 mg/kg) and
xylazine (10 mg/kg) anesthesia, intraperitoneally according to
a new method of hind-limb immobilization described by Kha-
juria et al.9
Rats were divided into 5 groups (6 rats per group). 1 –
non-immobilized (negative control) group; 2 – RHLI (positive
control) for 20 weeks; 3 – RHLI for 10 weeks, and then RHLI plus
ZOL (50 g/kg, single intravenous dose) for another 10 weeks;
4 – RHLI for 10 weeks, and then RHLI plus ALF (0.5 g/kg, oral
gauge daily) for another 10 weeks; 5 – RHLI for 10 weeks, then
RHLI plus ALF (0.5 g/kg, oral gauge daily) plus ZOL (50 g/kg,
single intravenous dose) for another 10 weeks. Oral gauge daily
in case of RHLI groups treated with ALF and ZOL plus ALF
required some animal handling and created some stress to
the animals. Therefore, non-immobilized (negative control)
and RHLI (positive control) and RHLI plus ZOL groups were
orally administered vehicle (normal saline) for 10 weeks. All
RHLI rats were single housed in polypropylene cages (size:
421 mm × 290 mm × 190 mm with gap of 7 mm between wires)
during the experimental period. The medication dosages used
in this experiment were selected from our previous study
conducted on rat model of postmenopausal osteoporosis.17 0 1 5;5 5(3):240–250
At the end of treatment study, all groups were euthanized
by an overdose of anesthesia. In all rats, immobilized (right)
and non-immobilized (left) were excised and cleared of fat
and connective tissues. Femurs were soaked in saline solution
gauze and frozen at −20 ◦C till further analysis. Both immo-
bilized (right) and non-immobilized (left) femurs were used
for measurement of bone porosity, biomechanical properties,
femoral length, femoral dry and ash weight.
Final  body  weight  and  femoral  length
Body weight (expressed in grams) was monitored at the start
and the end of the experiments. Femoral length was measured
with a precision caliper.
Measurement  of  bone  porosity  by  X-ray  imaging
The right femurs of all animals were scanned with foX-Rayzor,
which is a portable X-ray inspection system equipped with
“Calculate histogram” tool software, according to the method
described previously.22 Brieﬂy, for X-ray analysis of rat femur,
whole femur was divided into four equal ﬁelds, which included
distal femoral epiphysis (R1), femoral shaft (R2 and R3) and
proximal femur (R4).
Biomechanical  bone  strength  testing
The mechanical properties of the femoral mid-shaft were
measured using three-point bending, using a universal test-
ing machine (BISS Makron, Bangalore, India). Femur strength
was assessed by three point bending as previously described.22
Brieﬂy, femurs were removed from the −20◦ C freezer and
rehydrated in a saline solution for 4 h at room temperature.
Hydrated weight of the bones was determined using a four
decimal place digital scale. Length of the bones was measured
with calipers. Specimens were placed on two supports that
were separated by a distance of 12 mm and bent until frac-
ture by lowering the crosshead positioned at the mid-shaft at
a constant speed of 0.033 mm/s. From the load–displacement
curve, the peak load (N), the ultimate stiffness (N/mm), and the
toughness (mJ) were obtained. Ultimate stress (strength) and
Young’s modulus were derived from load–deformation curves
obtained by using equations described previously.22
Measurement  of  femoral  dry  weight  and  ash  weight
After conducting three point bending test, the femurs of all
animals were dehydrated with ethanol, and fat was removed
with diethyl ether. After the bones were allowed to air-dry,
the dry bone weight was measured with a digital weighing
balance. Next, the dried femurs were burned to ash at 900 ◦C
for 5 h, and their ash weight was measured.
Statistical  analysis
All data were expressed as the mean ± standard devia-
tion (SD). For all the data, comparisons between different
treatments were analyzed by one-way ANOVA, followed by
Tukey’s multiple comparison tests, and differences between
the immobilized side and the non-immobilized side were
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ompared with the Wilcoxon signed-rank test. In all cases, a
robability error of less than 0.05 was selected as the criterion
or statistical signiﬁcance. Graphs were drawn using Graph
ad Prism (version 5.0 for Windows).
esults
ffect  of  different  treatments  on  body  weight  and  femoral
ength
en weeks after RHLI, the body weights were signiﬁcantly
ower for animals in the RHLI (positive control) and RHLI treat-
ent groups compared with the non-immobilized normal
roup. This difference had become greater at the end of the
xperiment (RHLI for another 10 weeks). However, there were
o statistically signiﬁcant differences in weights observed
etween any of the active treatment groups and that of the
HLI (positive control) group (Table 1).
There were no signiﬁcant differences in immobilized
right) femoral length between positive control group
39.89 ± 1.3 mm),  ZOL group (40.23 ± 4.7 mm),  ALF group
39.78 ± 8.4 mm),  ZOL + ALF group (40.69 ± 10.4) and normal
ontrol group (41.09 ± 2.2 mm).  Moreover, there were no sig-
iﬁcant differences between the immobilized (right) side and
on-immobilized (left) side (data not shown).
ffect  of  different  treatments  on  bone  porosity
he X-ray image  shows the difference in the X-ray transmis-
ion intensity depending on the porosity of the sample. The
-ray transmission intensity is directly proportional to the
orosity. The effects of RHLI and subsequent treatment with
ll therapeutic interventions on the porosity of the right femur
ere measured by X-ray imaging, as shown in Fig. 1. X-ray
ntensity for the RHLI (positive control) group at R1 (distal epi-
hysis), R2 (mid-shaft: distal) R3 (mid-shaft: proximal) and R4
proximal epiphysis) was signiﬁcantly higher than those for
he non-immobilized normal group, which indicates an immo-
ilization elicited increase in bone porosity in these areas.
Table 1 – Effects of the different treatments on body
weight.
Group Body weight
Pre-treatment (g) Post-treatment (g)
Normal control 253.2 ± 10.65a 320.1 ± 13.39a
RHLI positive control 230.1 ± 18.22 216.6 ± 9.01
RHLI + ZOL 229.4 ± 11.22 218.0 ± 10.19
RHLI + ALF 232.8 ± 17.15 223.4 ± 12.18
RHLI + ZOL + ALF 225.8 ± 13.34 212.6 ± 11.13
Pre-treatment shows the data on the day prior to the start of treat-
ment. Post-treatment shows data on the ﬁnal day of the treatment.
Data are expressed as the mean ± S.D (n = 6), evaluated by one-way
ANOVA followed by Tukey’s multiple comparison test.
a p < 0.001, compared to RHLI (positive control) group. All groups
except normal group underwent right hind-limb immobilization
(RHLI). 5;5 5(3):240–250 243
After 10 weeks of therapy, all active treatments (single and
combined) succeeded in decreasing bone porosity in RHLI rats.
X-ray transmission intensity values at R1 (distal femoral epi-
physis) for ZOL, ALF and ZOL + ALF groups was lower than
those of RHLI (positive control) group (p < 0.001). Similarly, the
X-ray transmission intensity values at R2 (distal femoral shaft)
for ZOL, ALF and ZOL + ALF groups was lower than those of
RHLI (positive control) group (p < 0.01; p < 0.05 and p < 0.001
respectively). Likewise, the X-ray transmission intensity val-
ues at R3 (proximal femoral shaft) for ZOL, ALF and ZOL + ALF
groups was lower than those of RHLI (positive control) group
(p < 0.01; p < 0.001 and p < 0.001 respectively). Furthermore, the
X-ray transmission intensity values at R4 (proximal femoral
epiphysis) for ZOL, ALF and ZOL + ALF groups was lower than
those of RHLI (positive control) group (p < 0.01; p < 0.01 and
p < 0.001 respectively). In contrast, the X-ray transmission
intensity of the ZOL + ALF group was signiﬁcantly lower than
that of the ZOL and ALF groups at R1, R2, R3 and R4 regions
(p < 0.05).
Effect  of  different  treatments  on  mechanical  properties  in
the femoral  mid-shaft
Fig. 2 shows the peak load, ultimate stiffness, toughness, ulti-
mate strength and Young’s modulus in the femoral mid-shaft,
respectively. Three-point bending tests of the right femur indi-
cated that RHLI caused signiﬁcant reductions in the peak load,
ultimate stiffness, toughness, ultimate strength and Young’s
modulus compared with those in non-immobilized normal
group (p < 0.001).
In ZOL, ALF and ZOL + ALF groups, the peak load of the
femur was signiﬁcantly higher than in the RHLI (positive
control) group (p < 0.05; p < 0.01 and p < 0.001, respectively).
Similarly, ZOL, ALF and ZOL + ALF groups, the ultimate stiff-
ness of the femur was signiﬁcantly higher than in the
RHLI (positive control) group (p < 0.01; p < 0.01 and p < 0.001
respectively). The toughness of the femur in the ZOL, ALF
and ZOL + ALF groups was signiﬁcantly higher than in the
RHLI (positive control) group (p < 0.01; p < 0.05 and p < 0.001
respectively). In all single treatments, the toughness was sig-
niﬁcantly lower than that in the ZOL + ALF group (p < 0.05).
Moreover, ZOL, ALF and ZOL + ALF groups, the ultimate
strength of the femur was signiﬁcantly higher than in the
RHLI (positive control) group (p < 0.001). In ZOL and ALF groups,
the ultimate strength was signiﬁcantly lower than that in
the ZOL + ALF group (p < 0.01; p < 0.001, respectively). Further-
more, the Young’s modulus of the ZOL, ALF and ZOL + ALF
groups was signiﬁcantly increased when compared with the
RHLI (positive control) group (p < 0.05; p < 0.01; p < 0.01 and
p < 0.001, respectively). In all single treatments, the Young’s
modulus was signiﬁcantly lower than that in the ZOL + ALF
group (p < 0.05).
Comparison  of  the  effect  of  different  treatments  on  dry  and
ash weights  of  immobilized  and  non-immobilized  femurs  in
rats
RHLI induced a signiﬁcant decrease (p < 0.001) in dry and ash
weights in immobilized control rat femurs compared to non-
immobilized normal control rats (Table 2). The RHLI femur of
rats treated with single and combined treatments, dry and
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Fig. 1 – Effect of zoledronic acid and alfacalcidol, alone or in combination on femoral porosity. Bone porosity of R1: distal
femoral epiphysis, R2: distal femoral shaft, R3: proximal femoral shaft, R4: proximal femoral epiphysis. Data are shown as
the mean ± SD (n = 6), evaluated by Tukey’s multiple comparison test. *p < 0.05; **p < 0.01; ***p < 0.001, compared to RHLI
(positive control) group; ap < 0.05, compared to ZOL + ALF group. All groups except normal group underwent right hind-limb
immobilization (RHLI).
Table 2 – Effect of immobilization and different treatments on dry bone and ash weight.
Group Left non-immobilized femur Right immobilized femur
Dry bone weight
(mg/bone)
Bone ash weight
(mg/bone)
Dry bone weight
(mg/bone)a
Bone ash weight
(mg/bone)a
Normal control 630.7 ± 8.1 381.4 ± 7.7 639.8 ± 12.2b 385.7 ± 9.4b
RHLI positive control 620.5 ± 10.9 368.9 ± 4.3 543.9 ± 15.5 321.5 ± 11.5
RHLI + ZOL 622.1 ± 18.1 379.1 ± 7.2 593.7 ± 13.7b,c 351.7 ± 9.8b,c
RHLI + ALF 627.5 ± 12.1 382.4 ± 9.6 583.5 ± 9.4 b,c 349.5 ± 7.6b,c
RHLI + ZOL + ALF 640.7 ± 14.8 392.2 ± 13.6 619.1 ± 12.1b 369.9 ± 9.4b
Data are expressed as the mean ± S.D (n = 6), evaluated by one-way ANOVA followed by Tukey’s multiple comparison test.
a Indicates, for the parameter, a signiﬁcant difference of the active treatments between the two.
b p < 0.001, compared to immobilized RHLI (positive control) group; legs.
c p < 0.05 compared to ZOL + ALF group.
r e v b r a s r e u m a t o l . 2 0 1 5;5 5(3):240–250 245
No
rm
al 
co
ntr
ol
RH
LI 
co
ntr
ol
RH
LI 
+ Z
OL
RH
LI 
+ A
LF
RH
LI 
+ Z
OL
 + 
AL
F
No
rm
al 
co
ntr
ol
RH
LI 
co
ntr
ol
RH
LI 
+ Z
OL
RH
LI 
+ A
LF
RH
LI 
+ Z
OL
 + 
AL
F
0
50
100
150 ***
***
* **
Pe
ak
 lo
ad
 (N
)
0
100
200
300
**
*** *****
Ul
tim
at
e
St
iff
ne
ss
 (N
/m
m)
No
rm
al 
co
ntr
ol
RH
LI 
co
ntr
ol
RH
LI 
+ Z
OL
RH
LI 
+ A
LF
RH
LI 
+ Z
OL
 + 
AL
F
No
rm
al 
co
ntr
ol
RH
LI 
co
ntr
ol
RH
LI 
+ Z
OL
RH
LI 
+ A
LF
RH
LI 
+ Z
OL
 + 
AL
F
No
rm
al 
co
ntr
ol
RH
LI 
co
ntr
ol
RH
LI 
+ Z
OL
RH
LI 
+ A
LF
RH
LI 
+ Z
OL
 + 
AL
F
0
10
20
30
40
50
*
a
***
***
**
a
To
ug
hn
es
s 
(m
J)
0
100
200
300
***
***
b
***
c
***
Ul
tim
at
e
st
re
ng
th
 (M
Pa
)
0
2
4
6
**
a
***
***
**
a
Yo
un
g's
M
od
ul
us
 (G
Pa
)
Fig. 2 – Effects of zoledronic acid, alfacalcidol, or zoledronic acid plus alfacalcidol on the mechanical strength of the femoral
diaphysis. The diaphysis was subjected to three-point bending to failure, which provided data on peak load, ultimate
stiffness, toughness, ultimate strength, and Young’s modulus. Data are shown as the mean ± SD (n = 6), evaluated by Tukey’s
multiple comparison test. *p < 0.05; **p < 0.01; ***p < 0.001, compared to RHLI (positive control) group; a p < 0.05; b p < 0.01, c
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M < 0.001; compared to ZOL + ALF group. All groups except no
sh weights were signiﬁcantly heavier than those in the RHLI
positive control) group. The RHLI femur of the rats treated
ith ZOL + ALF, the dry weight was signiﬁcantly heavier than
hose in ZOL or ALF treated groups (p < 0.05 in the ALF group).
oreover, the RHLI femur of the rats treated with ZOL + ALFl group underwent right hind-limb immobilization (RHLI).
group, the ash weight was signiﬁcantly heavier than those
in ZOL and ALF treated groups (p < 0.05 in the ALF group). In
the left non-immobilized femurs, no signiﬁcant difference
was observed between single and combined treated and
non-immobilized normal groups.
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Comparison  between  non-immobilized  (left)  leg  and
immobilized  (right)  leg  with  in  a  same  group
The bone porosity and mechanical properties of the left and
right legs are plotted as “split-bar” diagrams in Figs. 3 and 4,
respectively. An asterisk indicates that there was a signiﬁ-
cant difference between the left and right leg within the same
group. At R1, R2, R3 and R4 regions, the X-ray transmission
intensity for the immobilized side (right) seemed signiﬁcantly
higher than those from the non-immobilized side (left) in the
RHLI (positive control) group (p < 0.001). Similarly, at R1, R2, R3
and R4 regions, the X-ray transmission intensity for the immo-
bilized side (right) seemed signiﬁcantly higher than those from
the non-immobilized side (left) in the RHLI groups treated with
ZOL or ALF (p < 0.05). In contrast, the RHLI group treated with
ZOL + ALF showed full protection against disuse osteoporosis
at R1, R2, R3 and R4 regions, as indicated by X-ray transmission
intensity values (Fig. 3).
At the femoral mid-diaphysis (three-point bending test),
the effect of immobilization was very pronounced in RHLI
(positive control) group; that is, the immobilized side (right)
had signiﬁcantly lower values of strength parameters includ-
ing peak load, ultimate stiffness, fracture toughness, ultimate
strength and Young’s modulus than the non-immobilized side
(left) (p < 0.001). Similarly, in the RHLI groups treated with
ZOL or ALF, the immobilized side (right) had signiﬁcantly
(p < 0.01) lower values of strength parameters including peak
load, ultimate stiffness, fracture toughness, ultimate strength
and Young’s modulus than the non-immobilized side (left). In
contrast, the RHLI group treated with ZOL + ALF showed full
protection against immobilization (Fig. 4).
Discussion
To our knowledge, the combined effects of anti-resorptive
and anabolic agents on the skeleton have not specially been
assessed in rat model of disuse osteoporosis. The present
study was conducted to clarify the efﬁcacy of combined
administration of ZOL and ALF on overall quality of bone in
RHLI rats. The results of this study showed that ZOL and ALF
monotherapy was able to counteract the bone loss in a rat
model of disuse osteoporosis. The anti-osteoporotic property
of ZOL plus ALF combination therapy appeared to be more
effective when compared to ZOL or ALF monotherapy. Thus,
we conﬁrmed the beneﬁcial effects of combined administra-
tion of ZOL and ALF for treatment of disuse osteoporosis in
rats.
Body weight in the normal group was greater than in the
RHLI (positive control) group. This may have been due to the
anesthesia administered during the RHLI procedure. Reduced
eating and overall reduced mobility are other possible factors
that may have contributed in a minor way to the development
of lower body weight and bone loss. Earlier studies have shown
a similar decrease in body weight after RHLI.9,23 The length
of the femur of the immobilized limb was not signiﬁcantly
different from that of the non-immobilized intact femur of the
same rat, suggesting that the longitudinal growth of the bone
is not retarded in these animals. It is therefore more  likely that
we are here dealing with immobilization osteoporosis rather
than simple growth retardation. 0 1 5;5 5(3):240–250
Prominent increase in bone porosity was observed at R1,
R2, R3 and R4, after immobilization of right hind-limb. The
increase in the bone porosity at R1, R2, R3, R4 regions of
rat femoral bone, due to unloading of right hind-limb was
suppressed by treatment with ZOL, ALF and ZOL + ALF. In
the analysis of the bone porosity of rat femur using X-ray
imaging, it was found that combination therapy with ZOL
+ ALF was statistically superior to ZOL or ALF monotherapy
in suppressing the increase in bone porosity due to RHLI. This
indicates that combination therapy with ZOL + ALF thickens
and strengthens cortical bone.
It should be noted that, in rats treated with ZOL, ALF and
ZOL + ALF, dry and ash weights in the right immobilized femur
were signiﬁcantly greater than those of the RHLI (positive con-
trol) group. Moreover, in the animals treated with combined
therapy of ZOL + ALF, dry and ash weights in the right immo-
bilized femur were signiﬁcantly greater than those of the ZOL
or ALF groups. These results showed that the combined treat-
ment with ZOL + ALF is beneﬁcial for increasing the mass of
rat femoral bones that was decreased due to RHLI.
Bone mechanical properties are related to bone density,
architecture, connectivity and mineralization.23 Immobiliza-
tion results in decreased mechanical properties9,24 and the
same was observed in the present study. In this experiment,
the mechanical properties of the rat femoral bone decreased
in RHLI (positive control) group when compared to non-
immobilized normal control group, suggesting an increase
in the fragility of the cortical bone of RHLI rats. Results of
the bending test in rats treated with ZOL, ALF and ZOL + ALF
indicate higher ultimate peak load, stiffness, energy, bending
stress and Young’s modulus compared to RHLI (positive con-
trol) group rats. Combination therapy with ZOL 50 + ALF was
statistically superior to ZOL or ALF monotherapy at increasing
femoral mid-shaft toughness, ultimate strength, and Young’s
modulus.
Comparison made between non-immobilized (left) leg and
immobilized (right) leg within a same group showed that bone
properties were improved by all therapeutic interventions, but
the marked osteopenia induced by RHLI was not completely
corrected with ZOL or ALF monotherapy. In contrast, com-
bined treatment with ZOL + ALF showed full protection against
disuse osteoporosis, suggesting that the combination therapy
has a therapeutic advantage over each drug monotherapy for
the treatment of disuse osteoporosis.
Osteoporosis therapeutics has been dominated by anti-
resorptive agents, mainly bisphosphonates (risedronate,
alendronate, ibandronate, pamidronate, zoledronic acid, etc.)
which prevent further bone loss in established osteoporosis
but do not change the bone mass or replenish the already lost
bone.7,10,25 In the present experimental research we  preferred
ZOL over other bisphosphonates available in India. ZOL has
several advantages over other bisphosphonates: (1) the obvi-
ous advantage of ZOL over other bisphosphonates is the high
level of adherence that is possible under the controlled envi-
ronment of a once yearly infusion administered under medical
supervision. Considering the low rates of adherence to oral
26bisphosphonates, this is a signiﬁcant medical advance ; (2)
oral bisphosphonates are not easily absorbed by the intes-
tine and exhibit variable bioavailability. Therefore, high doses
are required to be administered orally which, cause adverse
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Fig. 3 – Femoral porosity for the non-immobilized (left bar) and the immobilized (right bar) side with in the same group.
Asterisk denotes signiﬁcant difference between the non-immobilized side and the immobilized side (mean ± SD). All groups
except normal group underwent right hind-limb immobilization (RHLI).
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avents like esophagitis7; (3) it was found that under conditions
ikely to stimulate bisphosphonate binding onto bone, ZOL has
igher binding afﬁnity among all other bisphosphonates for
one hydroxyapatite27; (4) the cost of ZOL is comparable to
he annual cost of oral bisphosphonates and less than the
ost of the other intravenous bisphosphonate (ibandronate),
hich is administered every 3 months.27 However, parenteral
dministrations of bisphosphonates have shown acute phase
esponse, hypocalcemia and secondary hyperparathyroidism,
usculoskeletal pain, renal complications, osteonecrosis of
he jaw and ocular events in some cases.7,27,28 The results of
ur previous study showed that a lower dose of ZOL (50 g/kg,
ingle intravenous dose) had showed similar promising and
eneﬁcial effects in treating osteoporosis when compared
ith the therapeutic dose of ZOL (100 g/kg, single intravenous
ose) in estrogen deﬁcient rats.29 Therefore, to reduce the risk
f known adverse drug reactions by ZOL, we chose a lower
ose of ZOL (50 g/kg, single intravenous dose).
ALF is used to treat osteoporosis because it exerts both
nabolic and antiresorptive effects on the skeleton.13,18,19However, higher doses of ALF may increase the risk of
hypercalciuria or hypercalcemia. On the other hand, treat-
ment with ZOL may cause hypocalcemia by suppression of
bone resorption.17 The different mechanisms of ZOL and
ALF suggest that a combination therapy using ZOL  with
ALF may eliminate or minimize the risk of known adverse
drug reactions previously seen by these two  drugs when
administered alone. Based on the results of our previous and
present ﬁndings, we  propose that combination therapy with
ZOL + ALF acts by increasing bone formation (by stimulating
the formation and action of osteoblast cells) and decreasing
bone resorption (by inducing osteoclast apoptosis), thus
rebalancing bone turnover in favor of bone formation, an
effect that results in increased bone mass and strength.
This can possibly explain how combination therapy with
ZOL + ALF was more  effective than ZOL or ALF monotherapy
in increasing bone mass and strength in RHLI rats.This study has several limitations: (1) rats are quadrupeds,
and therefore experience a different loading pattern from that
of humans; (2) the remodeling pattern in rats is different from
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Fig. 4 – Mechanical properties for the non-immobilized (left bar) and the immobilized (right bar) side with in the same
group. The femoral mid-shaft was subjected to three-point bending to failure, which provided data on peak load, ultimate
stiffness, toughness, ultimate strength, and Young’s modulus. Asterisk denotes signiﬁcant difference between the
non-immobilized side and the immobilized side (mean ± SD). All groups except normal group underwent right hind-limb
immobilization (RHLI).
that of humans; (3) in the present study, a growing rat model
was used. Thus, maturation-related gains in bone mass could
not be ignored in RHLI rats; (4) furthermore, the effect of ZOL
and ALF on cortical porosity, which could be observed in aged
RHLI rats was not assessed. Therefore, the results of present
study cannot be translated into human with primary disuse
osteoporosis. Thus, further studies are needed to conﬁrm thebeneﬁcial effects of combined administration of ZOL and ALF
on the bone mass in RHLI rats.Conclusions
The current in vivo study ﬁrstly demonstrated that com-
bination therapy with ZOL + ALF therapy is highly effective
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n improving the bone properties in an rat model of disuse
steoporosis, suggesting that the combination therapy has a
herapeutic advantage over ZOL or ALF monotherapy for the
reatment of disuse osteoporosis induced by mechanical inac-
ivity. As such, this combined regimen may be of interest for
urther evaluation in clinical studies.
onﬂicts  of  interest
he authors declare no conﬂicts of interest.
cknowledgements
uthors would whole heartedly thank Prof. B.G. Shivananda,
rincipal, Al-Ameen College of Pharmacy for his kind support
nd encouragement to carry out this project. The authors are
hankful to Mr. B. K Jain, Naprod Life Sciences, Maharash-
ra, India for providing gift sample of Zoledronic acid. The
uthors also gratefully acknowledge the contribution of Mr.
ijay Kumar and Mr. Manish Kumar Priydarshi from Depart-
ent of Aerospace Engineering, Indian Institute of Science, in
arrying out the X-ray imaging and three point-bending tests.
 e  f  e  r  e  n  c  e  s
1. Li CR, Zhang GW, Niu YB, Pan YL, Zhai YK, Mei QB.
Antiosteoporosis effect of Radix Scutellariae extract on
density and microstructure of long bones in tail-suspended
Sprague-Dawley rats. Evidence-Based Complem Alternat
Med. 2013;2013:753703.
2. Barou O, Lafage-Proust MH, Martel C, Thomas T, Tirode F,
Laroche N, et al. Bisphosphonate effects in rat unloaded
hindlimb bone loss model: three-dimensional
microcomputed tomographic, histomorphometric, and
densitometric analyses. J Pharmacol Exp Ther. 1999;291:321–8.
3. Waters DJ, Caywood DD, Turner RT. Effect of tamoxifen citrate
on  canine immobilization (disuse) osteoporosis. Vet Surg.
1991;20:392–6.
4. Russell RG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of
action of bisphosphonates: similarities and differences and
their potential inﬂuence on clinical efﬁcacy. Osteoporos Int.
2008;19:733–59.
5. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA.
Once-yearly zoledronic acid for treatment of postmenopausal
osteoporosis. N Engl J Med. 2007;356:1809–22.
6. Lambrinoudaki I, Vlachou S, Galapi F, Papadimitriou D,
Papadias K. Once-yearly zoledronic acid in the prevention of
osteoporotic bone fractures in postmenopausal women. Clin
Interv Aging. 2008;3:445–51.
7. Khajuria DK, Razdan R, Mahapatra DR. Drugs for the
management of osteoporosis: a review. Rev Bras Reumatol.
2011;51:365–82.
8. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY,
et  al. Zoledronic acid and risedronate in the prevention and
treatment of glucocorticoid-induced osteoporosis (Horizon): a
multicentre, double-blind, double-dummy, randomised
controlled trial. Lancet. 2009;373:1253–63.9. Khajuria DK, Disha C, Razdan R, Mahapatra DR, Vasireddi R.
Prophylactic effects of propranolol versus standard therapy
on a new model of disuse osteoporosis in rats. Sci Pharm.
2014;82:357–74.
2 5;5 5(3):240–250 249
0. Vegger JB, Nielsen ES, Brüel A, Thomsen JS. Additive effect of
PTH (1-34) and zoledronate in the prevention of disuse
osteopenia in rats. Bone. 2014 [Epub ahead of print].
1. Shiraishi A, Miyabe S, Nakano T, Umakoshi Y, Ito M, Mihara
M.  The combination therapy with alfacalcidol and
risedronate improves the mechanical property in lumbar
spine by affecting material properties in an ovariectomized
rat model of osteoporosis. BMC Musculoskelet Disord. 2009;
10:66.
2. Khajuria DK, Disha C, Razdan R, Mahapatra DR. Comparative
evaluation of zoledronic acid, alfacalcidol, and propranolol in
pharmacological correction of experimental osteoporosis. Lat
Am  J Pharm. 2013;32:968–76.
3. Erben RG. Vitamin D analogs and bone. J Musculoskelet
Neuronal Interact. 2001;2:59–69.
4. Schacht E, Dukas L, Richy F. Combined therapies in
osteoporosis: bisphosphonates and vitamin D-hormone
analogs. J Musculoskelet Neuronal Interact. 2007;7:174–84.
5. de Nijs RN, Jacobs JW, Lems WF, Laan RF, Algra A, Huisman
AM, et al. Alendronate or alfacalcidol in
glucocorticoid-induced osteoporosis. N Engl J Med.
2006;355:675–84.
6. Izawa Y, Makita T, Hino S, Hashimoto Y, Kushida K, Inoue T,
et al. Immobilization osteoporosis and active vitamin D:
effect of active vitamin D analogs on the development of
immobilization osteoporosis in rats. Calcif Tissue Int.
1981;33:623–30.
7. Khajuria DK, Razdan R, Mahapatra DR. Zoledronic acid in
combination with alfacalcidol has additive effects on
trabecular microarchitecture and mechanical properties in
osteopenic ovariectomized rats. J Orthop Sci. 2014 [Epub
ahead of print].
8. Iwamoto J, Matsumoto H, Takeda T, Sato Y, Xu E, Yeh JK.
Effects of alendronate and alfacalcidol on the femoral bone
mass and bone strength in orchidectomized rats. Chin J
Physiol. 2008;51(December):331–7.
9. Iwamoto J, Seki A, Takeda T, Sato Y, Yamada H, Yeh JK. Effect
of  risedronate on the cortical and cancellous bone mass and
mechanical properties in ovariectomized rats: a comparison
with the effects of alfacalcidol. J Nutr Sci Vitaminol.
2006;52:393–401.
0. Frediani B, Allegri A, Bisogno S, Marcolongo R. Effects of
combined treatment with calcitriol plus alendronate on bone
mass and bone turnover in postmenopausal osteoporosis:
two years of continuous treatment. Clin Drug Invest.
1998;15:235–44.
1. Malavolta N, Zanardi M, Veronesi M, Ripamonti C, Gnudi S.
Calcitriol and alendronate combination treatment in
menopausal women with low bone mass. Int J Tissue React.
1999;21:51–9.
2. Khajuria DK, Razdan R, Mahapatra DR, Bhat MR.
Osteoprotective effect of propranolol in ovariectomized rats:
a comparison with zoledronic acid and alfacalcidol. J Orthop
Sci. 2013;18:832–42.
3. Faibish D, Ott SM, Boskey AL. Mineral changes in
osteoporosis: a review. Clin Orthop Relat Res. 2006;443:
28–38.
4. Mosekilde L, Thomsen JS, Mackey MS,  Phipps RJ. Treatment
with risedronate or alendronate prevents hind-limb
immobilization-induced loss of bone density and strength in
adult female rats. Bone. 2000;27:639–45.
5. Shirke SS, Jadhav SR, Jagtap AG. Methanolic extract of
Cuminum cyminum inhibits ovariectomy-induced bone loss
in  rats. Exp Biol Med (Maywood). 2008;233(11):
1403–10.6. Schumann SA, Hickner J. Annual zoledronic acid infusion
lowers risk of fracture, death. J Fam Pract. 2007;56:
1013–6.
 o l . 2
2
2
2250  r e v b r a s r e u m a t
7. Papapoulos SE. Bisphosphonates: how do they work? Best
Pract Res Clin Endocrinol Metab. 2008;22:831–47.
8. Su K, Shi X, Varshney RR, Wang D. Transplantable delivery
systems for in situ controlled release of bisphosphonate in
orthopedic therapy. Expert Opin Drug Deliv. 2011;8:113–26. 0 1 5;5 5(3):240–250
9. Khajuria DK, Razdan R, Mahapatra DR. The combination
therapy with zoledronic acid and propranolol improves the
trabecular microarchitecture and mechanical property in an
rat model of postmenopausal osteoporosis. J Osteoporos.
2014;2014:586431.
